Adoptive immunotherapy of cancer with polyclonal, 10(8)-fold hyperexpanded, CD4(+ )and CD8(+ )T cells

por Wang, Li-Xin, Huang, Wen-Xin, Graor, Hallie, Cohen, Peter A, Kim, Julian A, Shu, Suyu, Plautz, Gregory E
Publicado 2004

Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials

por Kang, Yoon-Koo, Reck, Martin, Nghiem, Paul, Feng, Yan, Plautz, Gregory, Kim, Hye Ryun, Owonikoko, Taofeek K, Boku, Narikazu, Chen, Li-Tzong, Lei, Ming, Chang, Han, Lin, Wen Hong, Roy, Amit, Bello, Akintunde, Sheng, Jennifer
Publicado 2022